US Patent 8598333 SiRNA silencing of genes expressed in cancer
Patent 8598333 was granted and assigned to Alnylam Pharmaceuticals on December, 2013 by the United States Patent and Trademark Office.
Is a
Current Assignee
Date Filed
May 29, 2007
Date of Patent
December 3, 2013
Patent Application Number
11807872
Patent Citations Received
Patent Jurisdiction
Patent Number
Patent Primary Examiner
Find more entities like US Patent 8598333 SiRNA silencing of genes expressed in cancer
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
